SS Innovations International, Inc. (NASDAQ: SSII) has reported significant growth in the utilization and global reach of its SSi Mantra surgical robotic system, underscoring the company's expanding role in the robotic surgery market. As of September 8, 2026, the SSi Mantra has been used in 14,103 cumulative procedures, a 79% increase from 7,885 at the end of 2025. The installed base of systems has also grown 42%, reaching 238 units from 168. These figures highlight the rapid adoption of the platform across multiple markets.
The SSi Mantra is now installed in 12 countries, and approximately 1,500 physicians have been trained on the system. It has been used for more than 170 types of surgical procedures, demonstrating its versatility. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments indicate that the company is successfully penetrating new geographies and expanding its clinical applications.
In addition to general surgery, SS Innovations has reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of August 31, including a more than 13,600-mile telesurgery between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India. Such high-volume usage demonstrates the system's reliability and efficiency, which are critical factors for hospitals considering robotic-assisted surgery programs.
Looking ahead, the company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. Additionally, SS Innovations believes European Union CE marking certification can be obtained by year-end 2026. These regulatory milestones, if achieved, would open up two of the largest healthcare markets in the world, significantly expanding the company's addressable market and revenue potential.
The implications of this announcement are substantial for both the company and the broader healthcare industry. SS Innovations' mission is to make robotic surgery affordable and accessible to a larger segment of the global population. The SSi Mantra system, along with the SSi Mudra suite of surgical instruments, is designed to support a variety of procedures, including cardiac surgery. As an American company headquartered in India, SS Innovations is well-positioned to leverage cost advantages while targeting global markets. The growing procedure volume and installed base suggest that the company is gaining traction against larger competitors in the robotic surgery space.
For investors, the update provides concrete evidence of commercial progress. The 79% growth in procedures and 42% increase in installations indicate strong demand. The upcoming regulatory decisions in the U.S. and Europe are key catalysts that could drive further adoption. The company's newsroom, available at https://ibn.fm/SSII, offers ongoing updates.
To view the full report, visit https://ibn.fm/DJILj.
